Talimogene laherparepvec (T-VEC; Imlygic) for treatment of unresectable melanoma lesions

HAYES, Inc.
Record ID 32016000795
English
Authors' recommendations: Description of Technology: This report focuses on the use of Imlygic (talimogene laherparepvec, also known as OncovexGM-CSF and T-VEC [henceforth referred to as talimogene]; Amgen Inc.) for the treatment of malignant melanoma. Talimogene is the first oncolytic virus therapeutic agent to receive Food and Drug Administration marketing approval. Oncolytic viruses are nonpathogenic, genetically modified viral strains that selectively infect and kill neoplastic cells. Talimogene is a genetically modified live oncolytic herpes simplex virus that expresses granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF improves the systemic antitumor effects of talimogene and is widely used as a vaccine adjuvant. Talimogene is injected directly into cutaneous, subcutaneous, or nodal lesions that are visible, palpable, or can be accessed by ultrasound guidance. The injection volume is based upon the lesion size, and multiple lesions may be treated at each session provided that the total volume does not exceed 4.0 milliliters. Patient Population: Talimogene is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery.
Details
Project Status: Completed
Year Published: 2016
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
MeSH Terms
  • Humans
  • Adjuvants, Immunologic
  • Melanoma
  • Skin Neoplasms
Contact
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: saleinfo@hayesinc.com
Contact Email: saleinfo@hayesinc.com
Copyright: 2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.